Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: p53 signaling pathway (mmu04115)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Apaf1
KLA  ATP  ATP+KLA
 NM_001042558 apoptotic peptidase activating factor 1 (Apaf1), transcript variant 1, mRNA [NM_001042558] KLA 2.92 2.81 3.22 2.74 2.42 1.74 1.40
ATP 1.05 .99 .87 .81 1.61 2.03 1.46
KLA/ATP 2.90 2.78 2.01 1.69 1.56 2.77 2.73
Atm
KLA  ATP  ATP+KLA
 NM_007499 ataxia telangiectasia mutated homolog (human) (Atm), mRNA [NM_007499] KLA 1.86 1.97 2.17 1.67 1.20 .86 .79
ATP 1.09 1.17 1.01 .97 .61 .63 .69
KLA/ATP 2.11 2.24 1.55 1.46 .85 .75 .59
Bai1
KLA  ATP  ATP+KLA
 NM_174991 brain-specific angiogenesis inhibitor 1 (Bai1), mRNA [NM_174991] KLA 1.66 1.73 1.90 1.85 1.85 1.79 1.35
ATP .99 1.07 1.16 1.18 1.10 1.24 1.19
KLA/ATP 1.74 1.80 2.00 1.80 1.67 1.62 1.64
Bax
KLA  ATP  ATP+KLA
 NM_007527 Bcl2-associated X protein (Bax), mRNA [NM_007527] KLA 1.08 1.14 1.10 1.14 1.17 1.06 .92
ATP 1.06 1.05 1.02 1.25 1.26 .90 .86
KLA/ATP 1.11 1.19 1.30 1.34 1.34 .87 .71
Bbc3
KLA  ATP  ATP+KLA
 NM_133234 Bcl-2 binding component 3 (Bbc3), mRNA [NM_133234] KLA 1.53 1.37 1.05 1.26 .85 .64 .53
ATP .80 .68 .56 1.03 .64 .80 .35
KLA/ATP 1.40 1.09 .81 1.05 1.72 1.13 .54
Bid
KLA  ATP  ATP+KLA
 NM_007544 BH3 interacting domain death agonist (Bid), mRNA [NM_007544] KLA 1.03 1.08 1.09 1.14 1.01 .99 .68
ATP 1.06 1.11 .97 .89 1.04 1.17 1.08
KLA/ATP .88 1.09 .92 1.06 1.16 1.28 1.56
Casp3
KLA  ATP  ATP+KLA
 NM_009810 caspase 3 (Casp3), mRNA [NM_009810] KLA 1.66 1.94 2.47 2.61 3.01 2.96 1.44
ATP .90 .99 1.17 1.30 1.01 1.17 .86
KLA/ATP 1.55 1.87 2.40 2.35 2.27 2.84 2.52
Casp3
KLA  ATP  ATP+KLA
 U49929 ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] KLA 1.71 1.87 2.69 3.11 3.64 3.42 1.52
ATP 1.04 1.07 1.16 1.34 .98 1.27 .86
KLA/ATP 1.80 1.96 2.46 2.91 2.50 3.24 3.10
Casp8
KLA  ATP  ATP+KLA
 NM_009812 caspase 8 (Casp8), transcript variant 1, mRNA [NM_009812] KLA 2.41 2.53 3.20 3.26 2.75 2.78 1.57
ATP .91 .96 .66 .67 .54 1.53 1.52
KLA/ATP 2.47 2.52 2.08 2.41 1.41 2.50 2.77
Casp9
KLA  ATP  ATP+KLA
 NM_015733 caspase 9 (Casp9), mRNA [NM_015733] KLA .31 .31 .40 .66 .89 1.19 .91
ATP .88 .77 .91 .59 .43 .75 .93
KLA/ATP .26 .26 .30 .28 .80 1.06 .97
Ccnb1
KLA  ATP  ATP+KLA
 NM_172301 cyclin B1 (Ccnb1), mRNA [NM_172301] KLA .41 .37 .34 .29 .20 .18 .12
ATP 1.05 1.04 1.22 1.33 1.02 .54 .10
KLA/ATP .44 .37 .42 .39 .37 .22 .10
Ccnb2
KLA  ATP  ATP+KLA
 NM_007630 cyclin B2 (Ccnb2), mRNA [NM_007630] KLA .60 .51 .52 .39 .25 .15 .09
ATP .99 .89 1.32 1.14 .93 .55 .10
KLA/ATP .58 .52 .70 .59 .86 .47 .15
Ccnb3
KLA  ATP  ATP+KLA
 NM_183015 cyclin B3 (Ccnb3), mRNA [NM_183015] KLA 1.00 1.04 1.09 .93 1.03 1.05 1.03
ATP 1.00 1.02 .97 1.06 1.06 1.01 1.05
KLA/ATP 1.03 .99 1.04 1.04 1.10 1.12 1.03
Ccnd1
KLA  ATP  ATP+KLA
 S78355 gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] KLA .24 .23 .23 .24 .29 .47 .17
ATP 1.02 1.02 .88 .80 .52 .10 .21
KLA/ATP .27 .23 .22 .24 .27 .25 .14
Ccnd2
KLA  ATP  ATP+KLA
 NM_009829 cyclin D2 (Ccnd2), mRNA [NM_009829] KLA 12.92 13.66 11.94 12.37 11.11 5.44 1.53
ATP .98 .75 .50 .57 1.24 2.83 .40
KLA/ATP 11.19 11.62 10.34 7.96 7.92 7.10 2.57
Ccnd3
KLA  ATP  ATP+KLA
 NM_007632 cyclin D3 (Ccnd3), transcript variant 1, mRNA [NM_007632] KLA .60 .65 .86 1.02 1.91 2.26 1.45
ATP 1.05 1.14 .89 1.20 .74 .76 .99
KLA/ATP .70 .67 .54 .83 .61 1.19 1.45
Ccne1
KLA  ATP  ATP+KLA
 NM_007633 cyclin E1 (Ccne1), mRNA [NM_007633] KLA 1.13 1.14 1.13 .78 .51 .69 .55
ATP .92 .94 1.09 .93 .75 .71 .47
KLA/ATP 1.13 1.17 1.45 1.24 1.33 1.50 .85
Ccne2
KLA  ATP  ATP+KLA
 NM_001037134 cyclin E2 (Ccne2), transcript variant 1, mRNA [NM_001037134] KLA .34 .35 .42 .36 .35 .36 .26
ATP 1.02 1.11 1.01 .82 .58 .38 .23
KLA/ATP .36 .34 .44 .43 .41 .40 .25
Ccng1
KLA  ATP  ATP+KLA
 NM_009831 cyclin G1 (Ccng1), mRNA [NM_009831] KLA 1.16 1.21 1.21 1.19 1.14 1.02 .97
ATP .96 1.00 .95 .84 .72 .96 .99
KLA/ATP 1.14 1.08 1.01 .90 .79 1.05 1.52
Ccng2
KLA  ATP  ATP+KLA
 NM_007635 cyclin G2 (Ccng2), mRNA [NM_007635] KLA 4.69 4.19 4.37 2.50 1.85 1.04 .68
ATP 1.03 1.10 1.25 1.52 4.69 2.32 .48
KLA/ATP 4.55 4.78 5.00 4.02 5.17 2.54 1.25
Cd82
KLA  ATP  ATP+KLA
 NM_007656 CD82 antigen (Cd82), mRNA [NM_007656] KLA 1.68 1.80 1.89 1.69 1.95 1.67 1.62
ATP 1.03 1.02 .82 1.20 2.07 2.09 1.91
KLA/ATP 1.89 1.86 1.69 1.98 1.70 1.46 1.95
Cdc2a
KLA  ATP  ATP+KLA
 NM_007659 cell division cycle 2 homolog A (S. pombe) (Cdc2a), mRNA [NM_007659] KLA .72 .68 .65 .58 .58 .59 .48
ATP 1.01 1.05 1.21 1.06 .83 .77 .51
KLA/ATP .68 .63 .79 .70 .59 .59 .51
Cdk2
KLA  ATP  ATP+KLA
 NM_016756 cyclin-dependent kinase 2 (Cdk2), transcript variant 2, mRNA [NM_016756] KLA .68 .67 .62 .63 .60 .74 .73
ATP 1.02 1.14 .91 .92 .68 .71 .65
KLA/ATP .67 .64 .64 .64 .61 .74 .62
Cdk4
KLA  ATP  ATP+KLA
 NM_009870 cyclin-dependent kinase 4 (Cdk4), mRNA [NM_009870] KLA .66 .72 .65 .55 .46 .50 .71
ATP 1.03 1.02 .53 .65 .66 .63 .75
KLA/ATP .78 .61 .31 .42 .44 .62 .43
Cdk6
KLA  ATP  ATP+KLA
 AK030810 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830411I20 product:unclassifiable, full insert sequence [AK030810] KLA 1.05 .96 .67 .51 .48 .49 .45
ATP 1.02 .91 .78 .49 .50 .47 .44
KLA/ATP 1.01 .89 .65 .40 .36 .26 .49
Cdk6
KLA  ATP  ATP+KLA
 NM_009873 cyclin-dependent kinase 6 (Cdk6), mRNA [NM_009873] KLA 2.63 2.36 2.14 1.80 1.55 1.32 1.03
ATP 1.11 1.21 1.06 1.23 .94 1.30 2.08
KLA/ATP 2.58 2.69 2.24 2.25 1.38 .85 3.00
Cdkn1a
KLA  ATP  ATP+KLA
 NM_007669 cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM_007669] KLA 4.72 4.90 4.96 3.73 2.11 1.14 1.02
ATP 1.14 1.52 .95 1.69 1.47 2.21 .50
KLA/ATP 5.99 7.08 3.86 6.37 3.00 2.55 2.05
Cdkn2a
KLA  ATP  ATP+KLA
 NM_009877 cyclin-dependent kinase inhibitor 2A (Cdkn2a), transcript variant 1, mRNA [NM_009877] KLA .95 .95 .86 .96 .91 .90 .75
ATP 1.00 .99 .95 .95 .97 .89 .77
KLA/ATP .95 .96 .92 .94 .90 .85 .76
Chek1
KLA  ATP  ATP+KLA
 NM_007691 checkpoint kinase 1 homolog (S. pombe) (Chek1), mRNA [NM_007691] KLA .36 .35 .37 .36 .34 .44 .31
ATP 1.12 1.14 1.17 1.08 .64 .43 .32
KLA/ATP .37 .36 .48 .46 .49 .36 .25
Chek2
KLA  ATP  ATP+KLA
 NM_016681 CHK2 checkpoint homolog (S. pombe) (Chek2), mRNA [NM_016681] KLA .55 .54 .46 .55 .47 .52 .59
ATP 1.07 1.10 .83 .88 .64 .61 .62
KLA/ATP .54 .51 .49 .55 .56 .57 .46
Cycs
KLA  ATP  ATP+KLA
 NM_007808 cytochrome c, somatic (Cycs), nuclear gene encoding mitochondrial protein, mRNA [NM_007808] KLA 2.20 2.21 2.35 2.69 2.62 3.22 2.14
ATP .87 .89 1.31 1.05 1.06 1.20 1.26
KLA/ATP 1.88 2.04 2.86 2.26 2.57 2.45 2.03
Cyct
KLA  ATP  ATP+KLA
 NM_009989 cytochrome c, testis (Cyct), mRNA [NM_009989] KLA .93 1.01 1.00 .99 1.02 1.03 .96
ATP 1.01 .91 1.01 .99 .98 .95 .95
KLA/ATP 1.10 .96 .89 .89 1.10 1.05 .97
Ddb2
KLA  ATP  ATP+KLA
 NM_028119 damage specific DNA binding protein 2 (Ddb2), mRNA [NM_028119] KLA .72 .69 .72 .69 .67 .75 .83
ATP 1.21 1.11 1.21 1.05 .61 .49 .87
KLA/ATP .83 .78 .80 .72 .54 .55 .77
Ei24
KLA  ATP  ATP+KLA
 NM_007915 etoposide induced 2.4 mRNA (Ei24), mRNA [NM_007915] KLA .85 .86 .80 .76 .76 .72 .80
ATP 1.00 1.03 1.01 .96 .68 .62 .71
KLA/ATP .82 .79 .70 .70 .52 .64 .63
Fas
KLA  ATP  ATP+KLA
 AK086933 0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030012O08 product:tumor necrosis factor receptor superfamily, member 6, full insert sequence. [AK086933] KLA 6.31 6.56 6.33 6.70 4.93 3.74 2.48
ATP .95 1.04 1.33 1.55 1.85 6.00 2.77
KLA/ATP 5.67 7.16 7.71 7.73 6.02 5.79 7.85
Fas
KLA  ATP  ATP+KLA
 NM_007987 Fas (TNF receptor superfamily member 6) (Fas), mRNA [NM_007987] KLA 17.08 17.45 19.08 17.38 13.33 6.78 4.46
ATP .98 .96 1.64 3.05 5.58 12.91 1.89
KLA/ATP 16.57 17.25 26.06 23.57 22.03 16.74 13.29
Gadd45a
KLA  ATP  ATP+KLA
 NM_007836 growth arrest and DNA-damage-inducible 45 alpha (Gadd45a), mRNA [NM_007836] KLA .52 .72 .68 .82 1.11 .73 1.91
ATP .92 .85 1.20 3.38 7.86 3.35 3.64
KLA/ATP .54 .95 1.60 3.49 5.04 3.79 2.80
Gadd45b
KLA  ATP  ATP+KLA
 NM_008655 growth arrest and DNA-damage-inducible 45 beta (Gadd45b), mRNA [NM_008655] KLA 10.08 11.65 8.40 11.27 8.24 7.30 5.74
ATP 1.83 3.28 10.08 27.60 15.97 8.84 4.61
KLA/ATP 9.36 14.99 21.30 45.24 49.27 21.63 22.73
Gadd45g
KLA  ATP  ATP+KLA
 NM_011817 growth arrest and DNA-damage-inducible 45 gamma (Gadd45g), mRNA [NM_011817] KLA 2.18 2.14 2.95 3.62 3.22 4.69 1.21
ATP 1.01 1.74 8.49 11.83 4.60 5.94 5.94
KLA/ATP 2.58 3.99 12.54 13.16 12.25 12.41 12.33
Gtse1
KLA  ATP  ATP+KLA
 NM_013882 G two S phase expressed protein 1 (Gtse1), mRNA [NM_013882] KLA 1.26 1.16 1.16 1.13 .66 .46 .33
ATP 1.07 1.10 1.16 .95 .77 .88 .33
KLA/ATP 1.24 1.14 1.48 1.27 .83 .80 .41
Igf1
KLA  ATP  ATP+KLA
 AK050118 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118] KLA .13 .14 .15 .16 .22 .34 .48
ATP 1.78 2.05 1.37 .72 .34 .41 .58
KLA/ATP .24 .45 .50 .24 .20 .26 .68
Igf1
KLA  ATP  ATP+KLA
 NM_010512 insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512] KLA .84 .78 .76 .67 .54 .48 .59
ATP .97 .98 1.13 1.13 1.03 .88 .89
KLA/ATP .82 .81 .93 .86 .83 .65 .89
Igf1
KLA  ATP  ATP+KLA
 NM_184052 insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052] KLA .77 .82 .76 .65 .60 .52 .69
ATP 1.01 1.07 .98 1.06 1.03 .78 .94
KLA/ATP .89 .86 .77 .80 .75 .65 .89
Igfbp3
KLA  ATP  ATP+KLA
 AK045003 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130018L24 product:unclassifiable, full insert sequence. [AK045003] KLA .92 1.01 .99 .97 .98 .98 1.05
ATP 1.00 .91 1.13 1.00 1.00 1.01 .95
KLA/ATP .99 1.07 1.02 .94 .97 1.03 .98
Igfbp3
KLA  ATP  ATP+KLA
 NM_008343 insulin-like growth factor binding protein 3 (Igfbp3), mRNA [NM_008343] KLA .94 .88 .95 .93 .95 .96 .92
ATP .97 1.04 1.03 1.02 1.06 1.04 .90
KLA/ATP .95 .94 .92 .92 1.01 .96 .94
Igfbp3
KLA  ATP  ATP+KLA
 X81581 gb|M.musculus mRNA for insulin-like growth factor binding protein-3. [X81581] KLA .97 .94 1.00 1.05 .99 1.05 1.01
ATP 1.05 1.06 1.06 1.03 1.04 1.01 1.06
KLA/ATP .99 1.07 1.07 .99 .97 1.09 1.02
Lrdd
KLA  ATP  ATP+KLA
 NM_022654 leucine-rich and death domain containing (Lrdd), mRNA [NM_022654] KLA .93 .97 1.01 .99 .96 1.02 .78
ATP 1.03 1.01 .91 .91 .75 .82 .73
KLA/ATP 1.02 1.03 1.06 1.27 1.01 1.03 .95
Mdm2
KLA  ATP  ATP+KLA
 NM_010786 transformed mouse 3T3 cell double minute 2 (Mdm2), mRNA [NM_010786] KLA 1.77 1.59 1.98 1.51 1.77 1.60 1.77
ATP 1.01 1.21 1.36 3.24 5.04 2.08 1.36
KLA/ATP 1.89 1.86 2.93 5.65 5.98 2.78 2.64
Mdm4
KLA  ATP  ATP+KLA
 AK046448 adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230385P13 product:inferred: transformed mouse 3T3 cell double minute 4, full insert sequence [AK046448] KLA 1.75 1.65 1.90 1.62 1.65 1.20 1.08
ATP 1.17 1.24 1.00 .84 .88 .95 .96
KLA/ATP 2.02 2.12 1.62 1.21 1.00 .86 .91
Mdm4
KLA  ATP  ATP+KLA
 NM_008575 transformed mouse 3T3 cell double minute 4 (Mdm4), mRNA [NM_008575] KLA 2.25 2.37 2.53 2.90 4.05 4.96 7.58
ATP 1.05 1.06 1.13 .98 1.04 1.41 1.69
KLA/ATP 2.40 2.71 2.42 1.99 1.87 2.31 5.19
Mm.18103
3
KLA  ATP  ATP+KLA
 146134511 Unknown KLA .69 .70 .63 .52 .41 .47 .91
ATP 1.19 1.59 .84 1.57 .99 .48 1.33
KLA/ATP .91 .83 .39 .77 .45 .49 .74
Mm.27304
9
KLA  ATP  ATP+KLA
 119672895 Unknown KLA .23 .22 .22 .22 .30 .51 .16
ATP 1.08 1.05 .88 .78 .47 .09 .20
KLA/ATP .28 .22 .21 .24 .26 .22 .12
Mm.47351
0
KLA  ATP  ATP+KLA
 162287332 Unknown KLA 4.46 4.82 5.29 4.00 2.26 1.25 1.10
ATP 1.24 1.72 1.02 2.08 1.66 2.53 .55
KLA/ATP 6.11 7.67 4.29 6.99 3.11 2.86 2.30
Perp
KLA  ATP  ATP+KLA
 NM_022032 PERP, TP53 apoptosis effector (Perp), mRNA [NM_022032] KLA 1.11 .95 1.09 1.09 1.04 1.00 .97
ATP 1.05 .99 .97 1.06 1.09 1.77 1.42
KLA/ATP 1.07 1.02 1.02 1.03 1.01 1.31 1.63
Pmaip1
KLA  ATP  ATP+KLA
 NM_021451 phorbol-12-myristate-13-acetate-induced protein 1 (Pmaip1), mRNA [NM_021451] KLA .91 .86 1.19 .95 1.00 1.69 .90
ATP .83 .83 1.73 2.05 3.55 5.44 1.25
KLA/ATP .80 1.02 2.98 3.40 4.54 6.15 4.73
Ppm1d
KLA  ATP  ATP+KLA
 AK051509 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130053L12 product:protein phosphatase 1D magnesium-dependent, delta isoform, full insert sequence [AK051509] KLA .99 .99 .95 .97 .94 1.04 1.03
ATP .98 1.00 .92 .97 1.02 1.04 1.00
KLA/ATP .95 .89 1.05 .96 1.02 .97 1.02
Ppm1d
KLA  ATP  ATP+KLA
 NM_016910 protein phosphatase 1D magnesium-dependent, delta isoform (Ppm1d), mRNA [NM_016910] KLA .70 .73 .69 .67 .75 .88 .81
ATP 1.07 1.10 1.16 1.13 1.24 1.22 .87
KLA/ATP .75 .71 .81 .85 1.10 1.15 .86
Pten
KLA  ATP  ATP+KLA
 NM_008960 phosphatase and tensin homolog (Pten), mRNA [NM_008960] KLA .79 .73 .61 .59 .56 .70 1.00
ATP 1.04 1.11 1.07 1.12 1.03 1.38 .83
KLA/ATP .75 .69 .60 .74 .93 1.09 1.24
Rchy1
KLA  ATP  ATP+KLA
 NM_026557 ring finger and CHY zinc finger domain containing 1 (Rchy1), mRNA [NM_026557] KLA .51 .57 .70 1.01 1.04 .77 .66
ATP .97 .91 .91 .94 .99 .76 1.05
KLA/ATP .48 .50 .61 .62 .85 .97 .97
Rfwd2
KLA  ATP  ATP+KLA
 AK042587 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730008F16 product:unclassifiable, full insert sequence. [AK042587] KLA 1.35 1.38 1.24 1.23 1.04 1.07 1.08
ATP .94 .84 .97 .89 .86 .88 .84
KLA/ATP 1.21 1.27 1.23 1.04 .99 .90 .89
Rfwd2
KLA  ATP  ATP+KLA
 NM_011931 ring finger and WD repeat domain 2 (Rfwd2), mRNA [NM_011931] KLA 3.14 3.10 3.09 3.13 2.22 1.83 1.59
ATP .99 .88 1.00 .71 .71 1.15 .87
KLA/ATP 2.95 2.99 3.16 1.81 1.26 .97 1.17
Rprm
KLA  ATP  ATP+KLA
 NM_023396 reprimo, TP53 dependent G2 arrest mediator candidate (Rprm), mRNA [NM_023396] KLA .96 1.07 .96 .96 .94 1.02 1.02
ATP 1.02 .98 .99 1.00 1.02 .95 1.05
KLA/ATP .98 .97 .98 .96 .97 1.04 1.04
Rrm2
KLA  ATP  ATP+KLA
 NM_009104 ribonucleotide reductase M2 (Rrm2), mRNA [NM_009104] KLA .32 .27 .23 .17 .13 .13 .12
ATP .98 1.00 1.17 1.28 .66 .20 .08
KLA/ATP .28 .25 .30 .30 .23 .13 .08
Rrm2b
KLA  ATP  ATP+KLA
 NM_199476 ribonucleotide reductase M2 B (TP53 inducible) (Rrm2b), mRNA [NM_199476] KLA .93 .90 .89 .95 .97 1.00 1.13
ATP .96 .95 .95 .87 .75 .80 .90
KLA/ATP .84 .85 .89 .84 .78 .78 .88
Serpinb5
KLA  ATP  ATP+KLA
 NM_009257 serine (or cysteine) peptidase inhibitor, clade B, member 5 (Serpinb5), mRNA [NM_009257] KLA 1.01 .98 1.00 .99 .94 1.03 1.06
ATP 1.06 .96 .97 .99 .99 1.14 1.89
KLA/ATP .93 .97 1.03 1.07 1.16 1.40 1.84
Serpine1
KLA  ATP  ATP+KLA
 AK040662 adult male aorta and vein cDNA, RIKEN full-length enriched library, clone:A530009B11 product:serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1, full insert sequence. [AK040662] KLA 1.12 1.08 1.10 1.03 1.00 1.01 1.05
ATP 1.00 1.09 1.39 1.44 1.05 .95 .99
KLA/ATP 1.09 1.10 1.02 1.03 1.08 1.19 1.02
Serpine1
KLA  ATP  ATP+KLA
 NM_008871 serine (or cysteine) peptidase inhibitor, clade E, member 1 (Serpine1), mRNA [NM_008871] KLA 36.00 31.05 27.47 23.20 11.59 4.14 1.47
ATP .97 1.15 3.43 11.58 8.77 7.42 2.16
KLA/ATP 31.47 33.70 38.54 30.90 22.06 23.68 18.57
Sesn1
KLA  ATP  ATP+KLA
 NM_001013370 sestrin 1 (Sesn1), mRNA [NM_001013370] KLA .11 .11 .13 .17 .25 .31 .26
ATP .92 .88 .59 .42 .21 .15 .35
KLA/ATP .11 .11 .14 .15 .16 .13 .17
Sesn2
KLA  ATP  ATP+KLA
 AK170547 NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630107J04 product:sestrin 2, full insert sequence. [AK170547] KLA 1.06 .89 .84 .67 .67 1.01 1.00
ATP .93 .81 .59 .54 3.67 1.76 .85
KLA/ATP 1.07 .80 .74 .49 2.83 2.17 1.13
Sesn2
KLA  ATP  ATP+KLA
 NM_144907 sestrin 2 (Sesn2), mRNA [NM_144907] KLA 1.08 1.00 .95 .77 .94 1.09 1.12
ATP 1.02 .97 .54 .80 4.04 .95 .95
KLA/ATP 1.23 1.13 .68 .74 2.71 1.42 1.40
Sesn3
KLA  ATP  ATP+KLA
 AK033655 adult male cecum cDNA, RIKEN full-length enriched library, clone:9130209A03 product:unclassifiable, full insert sequence [AK033655] KLA 1.67 1.61 1.80 1.59 .76 .71 .26
ATP .94 .81 .83 .55 .70 1.47 .23
KLA/ATP 1.49 1.37 1.67 .97 1.25 2.21 .47
Sesn3
KLA  ATP  ATP+KLA
 NM_030261 sestrin 3 (Sesn3), mRNA [NM_030261] KLA 3.05 2.93 3.76 4.13 2.24 1.82 .67
ATP .87 .88 1.11 .92 1.07 5.88 1.32
KLA/ATP 2.23 3.07 3.74 2.50 2.39 8.07 4.78
Sfn
KLA  ATP  ATP+KLA
 AF058798 14-3-3 protein sigma mRNA, complete cds. [AF058798] KLA 1.07 1.11 1.08 .99 .94 .97 1.05
ATP 1.06 1.05 1.04 1.29 3.02 3.37 1.05
KLA/ATP 1.13 1.13 1.06 1.17 2.83 3.94 2.23
Sfn
KLA  ATP  ATP+KLA
 NM_018754 stratifin (Sfn), mRNA [NM_018754] KLA .97 1.07 1.09 .99 .96 .97 1.02
ATP 1.03 1.08 1.07 1.33 1.98 2.15 .90
KLA/ATP 1.10 1.02 .97 1.23 1.99 2.58 1.39
Shisa5
KLA  ATP  ATP+KLA
 NM_025858 shisa homolog 5 (Xenopus laevis) (Shisa5), transcript variant 1, mRNA [NM_025858] KLA 1.10 1.10 1.17 1.10 1.21 1.35 1.54
ATP .99 1.04 .99 1.10 1.05 1.33 2.06
KLA/ATP 1.18 1.25 1.08 1.25 1.08 1.34 2.77
Siah1a
KLA  ATP  ATP+KLA
 NM_009172 seven in absentia 1A (Siah1a), mRNA [NM_009172] KLA 1.09 1.05 1.03 1.00 1.21 1.17 1.29
ATP .95 .99 .82 .77 1.02 .98 .98
KLA/ATP 1.06 1.04 .82 .78 .76 .85 1.06
Siah1b
KLA  ATP  ATP+KLA
 NM_009173 seven in absentia 1B (Siah1b), mRNA [NM_009173] KLA 1.20 1.10 1.09 1.08 1.00 .91 .84
ATP .97 .90 .79 .75 1.46 1.24 .84
KLA/ATP 1.06 1.08 .85 .66 1.21 1.40 1.08
Steap3
KLA  ATP  ATP+KLA
 AY029586 dudulin 2 mRNA, complete cds. [AY029586] KLA .99 1.00 1.00 1.01 .98 1.07 .94
ATP 1.02 .98 .95 .95 .98 1.05 .99
KLA/ATP .97 .94 1.01 .97 .94 .93 1.05
Steap3
KLA  ATP  ATP+KLA
 NM_001085409 STEAP family member 3 (Steap3), transcript variant 1, mRNA [NM_001085409] KLA .75 .69 .68 .58 .48 .52 .91
ATP 1.30 1.51 1.02 1.53 .99 .51 1.24
KLA/ATP .88 .89 .54 .73 .51 .50 .73
Thbs1
KLA  ATP  ATP+KLA
 NM_011580 thrombospondin 1 (Thbs1), mRNA [NM_011580] KLA 2.22 2.22 2.74 3.10 4.57 7.17 7.22
ATP 1.16 2.53 8.45 12.26 15.50 43.06 35.83
KLA/ATP 2.46 3.43 8.29 17.50 28.16 46.17 54.67
Trp53
KLA  ATP  ATP+KLA
 NM_011640 transformation related protein 53 (Trp53), mRNA [NM_011640] KLA 1.25 1.37 1.11 .86 .72 .71 .95
ATP 1.15 1.32 .90 1.85 1.26 .68 .70
KLA/ATP 1.66 1.49 .80 1.76 .81 .65 .74
Trp73
KLA  ATP  ATP+KLA
 BC069182 transformation related protein 73, mRNA (cDNA clone IMAGE:6826464) [BC069182] KLA .98 1.00 .95 .99 1.04 1.03 1.00
ATP 1.01 .97 1.01 1.06 1.04 1.01 1.08
KLA/ATP 1.02 .96 1.00 1.07 1.06 1.07 1.00
Trp73
KLA  ATP  ATP+KLA
 NM_011642 transformation related protein 73 (Trp73), mRNA [NM_011642] KLA 1.66 1.63 1.93 1.60 2.12 1.64 1.57
ATP 1.05 1.07 1.14 1.28 1.19 1.07 1.24
KLA/ATP 1.73 1.86 1.60 1.94 1.48 1.23 1.52
Tsc2
KLA  ATP  ATP+KLA
 NM_011647 tuberous sclerosis 2 (Tsc2), transcript variant 1, mRNA [NM_011647] KLA .91 .88 .87 .83 .83 .88 .99
ATP .91 .91 1.04 .88 .76 .68 .91
KLA/ATP .88 .89 .88 .76 .65 .67 .85
Zmat3
KLA  ATP  ATP+KLA
 AK048313 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130048F06 product:RIKEN cDNA 4930429B21 gene, full insert sequence. [AK048313] KLA .91 .90 .96 .87 .95 .92 .83
ATP .93 .94 .90 .85 .91 .87 .83
KLA/ATP .87 .90 .85 .86 .82 .89 .80
Zmat3
KLA  ATP  ATP+KLA
 NM_009517 zinc finger matrin type 3 (Zmat3), mRNA [NM_009517] KLA .43 .40 .35 .31 .28 .25 .25
ATP .90 .71 .57 .37 .63 .66 .18
KLA/ATP .39 .32 .29 .25 .49 .62 .17